Condition: T2DM (Type 2 Diabetes Mellitus) · Metformin · SGLT2-Inhibitors · Sponsor: Shinshu University
This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with chronic kidney disease (CKD).
This description comes directly from the study's public registry record.
Koichiro Kuwahara, MD, PhD · +81-263-37-3191 · kkuwah@shinshu-u.ac.jp
Always discuss trial participation with your own doctor first.
| Shinshu University | Matsumoto, Nagano, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05469659